Medical News

RSS

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.

4 May 2010

Empowering kids to make healthy choices can help combat obesity

Kids and teens often think they know what's best. When it comes to preventing childhood obesity, maybe we should listen to them, says Baker Harrell, executive director of ACTIVE Life, a non-profit organization that seeks to combat obesity with social activism.

4 May 2010

Ideal working environment can reduce psychosocial risks and health-related problems

The way people's work is organised can harm their health by causing a range of ailments, from cardiovascular disease to problems with mental health.

4 May 2010

Literacy-related barriers affect retention in Medicaid program for children: Research

Simplifying Medicaid renewal applications may help families keep their children enrolled in the government health insurance program, resulting in better medical care, according to research to be presented Saturday, May 1 at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia, Canada.

4 May 2010

New research contradicts studies on adolescents’ risk-taking behavior

Conventional wisdom holds that adolescents are susceptible to drug use and other risk-taking behavior. However, a one-size-fits-all approach to curbing these behaviors likely will be unsuccessful, according to research to be presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

4 May 2010

Boston Scientific commences enrollment in trial comparing SCS to spine reoperation in FBSS patients

Boston Scientific Corporation today announced the start of patient enrollment in the EVIDENCE Clinical Trial, which compares the therapeutic effectiveness and cost effectiveness of spinal cord stimulation (SCS) therapy to spine reoperation in patients with failed back surgery syndrome (FBSS). The first patient was enrolled by Joseph Buwembo, M.D. and Krishna Kumar, M.D., F.R.C.S.C., at Regina General Hospital in Regina, Saskatchewan, Canada.

4 May 2010

Novel combined immunotherapy promising for treatment of malignant brain tumors

A new Phase I clinical trial conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute in Los Angeles shows that two innovative treatment approaches may safely be combined to treat patients with highly aggressive, malignant brain tumors called gliomas. The results suggest that combining the two therapies might boost their effectiveness and supports the pursuit of additional studies on this approach to treating these tumors.

4 May 2010

Doctors often treat IBS patients with narcotics: Researchers

Doctors often unnecessarily treat irritable bowel syndrome with narcotics, according to a study led by University of North Carolina at Chapel Hill researchers.

4 May 2010

Lupus Canada to hold annual fundraising event

In the month of May residents in communities across Canada will participate in Lupus Canada's most important public awareness and fundraising event, Walk a Block for Lupus. Lupus Canada and its member organizations are holding their 9th Annual Walk a Block for Lupus campaign in conjunction with World Lupus Day to help increase awareness and funds for lupus.

4 May 2010

Repetitive transcranial magnetic stimulation induces remission in patients with treatment-resistant depression

Daily transcranial magnetic stimulation—an intervention that uses magnetic currents to activate certain brain areas—appears to help induce remission in patients with treatment-resistant depression, according to a report in the May issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 May 2010

Percentage of obese girls in the U.S. increases: HRSA study

The percentage of obese girls in the United States increased more than twice as much as the percentage of obese boys from 2003 to 2007, according to a study by researchers at the Health Resources and Services Administration.

4 May 2010

IFT supports FDA's salt reduction initiative

The Institute of Food Technologists (IFT) today offered its support to help the U.S. Food and Drug Administration (FDA) meet the challenges of reducing the amount of sodium in foods.

4 May 2010

New light-activated Photochemical Tissue Bonding technology helps treat battlefield injuries

Airmen's traumatic battlefield injuries may be more effectively treated by using a new light-activated technology developed as a result of research managed by Air Force Office of Scientific Research and supported by funds from the Office of the Secretary of Defense.

4 May 2010

Updated list of emergency medications and equipment for dental providers

Best practices for managing medical emergencies in dental clinics have evolved over the past decade to account for advances in knowledge and the development of new medications and medical equipment. Morton Rosenberg, DMD, of Tufts University School of Dental Medicine and an expert on dental anesthesiology, integrated existing guidelines with new information to create an updated list of emergency medications and equipment for dental providers, including an emergency preparedness checklist.

4 May 2010

Johns Hopkins researchers identify a key protein that triggers sarcoidosis

Lung researchers at Johns Hopkins have identified a possible protein trigger responsible for sarcoidosis, a potentially fatal inflammatory disease marked by tiny clumps of inflammatory cells that each year leave deep, grainy scars on the lungs, lymph nodes, skin and almost all major organs in hundreds of thousands of Americans.

4 May 2010

Beta version of Mental Health Social Network launched

Mental Health Social, LLC launches first beta version of its Mental Health Social Network, announces Colin Spencer Wood, company President and Chief Executive Officer. The beta version includes a new design/layout, an updated status page, added options in the profile, the ability for users to blog on a Word press multi-user blog system, where users have the option of adding their own google adsense ads, and several other site features.

4 May 2010

$Osteoporosis screening can reduce risk of future fractures$

Osteoporosis screening can reduce risk of future fractures

One in two women in the United States will have an osteoporosis-related fracture in her lifetime. However, according to a review article published in the May 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), only a few of these women will be tested and treated for osteoporosis, which if identified and treated, could dramatically decrease their risk of future fractures.

4 May 2010

Researchers study relationship between insurance status and head injury patient transfer

The Emergency Medical Treatment & Labor Act was enacted in 1986 to provide access to emergency medical care and transfer for all patients, regardless of immigration status or ability to pay.

4 May 2010

Women taking hormonal contraceptives are at highest risk of FSD: Study

Women taking non-oral and oral hormonal contraceptives were at highest risk of Female Sexual Dysfunction, according to a study of female German medical students published today in The Journal of Sexual Medicine. Interestingly, women taking non-hormonal contraceptives were at lowest risk for FSD, more than women not using any contraceptive.

4 May 2010

ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine

ADVENTRX Pharmaceuticals, Inc. today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site. The 6-month stability data are on track to support the submission of the New Drug Application (NDA) for Exelbine.

4 May 2010